John G Ullman & Associates Inc. Invests $3.98 Million in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

John G Ullman & Associates Inc. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 32,664 shares of the medical equipment provider’s stock, valued at approximately $3,975,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Schechter Investment Advisors LLC lifted its holdings in shares of Zimmer Biomet by 21.6% during the third quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock worth $476,000 after buying an additional 752 shares in the last quarter. Atria Wealth Solutions Inc. raised its stake in Zimmer Biomet by 5.9% in the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock valued at $2,312,000 after purchasing an additional 1,144 shares in the last quarter. International Assets Investment Management LLC raised its stake in Zimmer Biomet by 11,244.9% in the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock valued at $8,146,000 after purchasing an additional 66,345 shares in the last quarter. Amalgamated Bank raised its stake in Zimmer Biomet by 3.0% in the third quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock valued at $6,303,000 after purchasing an additional 1,631 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in Zimmer Biomet by 37.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock valued at $18,981,000 after purchasing an additional 42,539 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.95% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ZBH. Truist Financial boosted their price target on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research note on Friday, February 9th. Citigroup lifted their target price on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 9th. Canaccord Genuity Group reiterated a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a research report on Friday, February 23rd. Finally, Evercore ISI lifted their target price on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $139.39.

Zimmer Biomet Trading Up 0.1 %

Shares of Zimmer Biomet stock traded up $0.10 on Friday, reaching $119.43. 1,296,143 shares of the company’s stock were exchanged, compared to its average volume of 1,475,727. The company has a market capitalization of $24.54 billion, a P/E ratio of 24.42, a price-to-earnings-growth ratio of 2.23 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $149.25. The firm’s 50-day moving average is $126.39 and its two-hundred day moving average is $119.10. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same period last year, the business earned $1.88 EPS. Zimmer Biomet’s quarterly revenue was up 6.3% compared to the same quarter last year. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.